Aspirin metabolites are GPR35 agonists

Area of Science:

• Pharmacology
• Molecular Biology
• G protein-coupled receptor research

Background:

• Aspirin is a widely used medication for its anti-inflammatory, anti-platelet, anti-pyretic, and cancer-preventive properties.
• The complete molecular mechanisms underlying aspirin's diverse clinical effects are not fully understood and are unlikely to be solely due to cyclooxygenase inhibition.

Purpose of the Study:

• To investigate the potential role of aspirin metabolites in mediating aspirin's effects.
• To identify novel molecular targets for aspirin and its derivatives.

Main Methods:

• Screening of aspirin metabolites for activity at the G protein-coupled receptor 35 (GPR35).
• Characterization of agonist activity using biochemical and cellular assays.
• Identification of specific metabolites, such as 2,3,5-trihydroxybenzoic acid and salicyluric acid, as GPR35 agonists.

Main Results:

• Several aspirin metabolites exhibit agonist activity at the G protein-coupled receptor 35 (GPR35).
• 2,3,5-Trihydroxybenzoic acid, an aspirin catabolite, was identified as a potent GPR35 agonist.
• Salicyluric acid, a major metabolite of aspirin, also demonstrated activity at GPR35.

Conclusions:

• The findings suggest that the GPR35 agonist activity of certain aspirin metabolites may contribute to the observed clinical effects of aspirin.
• This study reveals a novel mechanism of action for aspirin, involving the GPR35 receptor pathway.
• Further research into GPR35 modulation by aspirin metabolites could lead to new therapeutic strategies.